Neumora gains after early-stage trial results for Alzheimer's product
Source: SeekingAlpha
2026-01-05 07:20:48 ET
More on Neumora Therapeutics
- Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs - Slideshow
- Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript
- Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset
- Neumora to initiate phase 1 study of oral obesity pill
- Seeking Alpha’s Quant Rating on Neumora Therapeutics
Read the full article on Seeking Alpha
For further details see:
Neumora gains after early-stage trial results for Alzheimer’s product
Neumora Therapeutics Inc.
NASDAQ: NMRA
NMRA Trading
-0.67% G/L:
$2.975 Last:
548,324 Volume:
$2.96 Open:
NMRA Latest News
February 04, 2026 07:00:00 am
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
NMRA Stock Data
$499,596,451
52,800,160
10.86%
30
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
